Cargando…

Artificial intelligence in clinical and translational science: Successes, challenges and opportunities

Artificial intelligence (AI) is transforming many domains, including finance, agriculture, defense, and biomedicine. In this paper, we focus on the role of AI in clinical and translational research (CTR), including preclinical research (T1), clinical research (T2), clinical implementation (T3), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bernstam, Elmer V., Shireman, Paula K., Meric‐Bernstam, Funda, N. Zozus, Meredith, Jiang, Xiaoqian, Brimhall, Bradley B., Windham, Ashley K., Schmidt, Susanne, Visweswaran, Shyam, Ye, Ye, Goodrum, Heath, Ling, Yaobin, Barapatre, Seemran, Becich, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841416/ https://www.ncbi.nlm.nih.gov/pubmed/34706145 http://dx.doi.org/10.1111/cts.13175

Ejemplares similares

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients
por: Samuel, Sophie, et al.
Publicado: (2023)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Confidence-based laboratory test reduction recommendation algorithm
por: Huang, Tongtong, et al.
Publicado: (2023)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)

Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome
por: Batista, Larissa I, et al.
Publicado: (2008)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Predicting multiple sclerosis severity with multimodal deep neural networks
por: Zhang, Kai, et al.
Publicado: (2023)

Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
por: Chen, Tenghui, et al.
Publicado: (2016)

Response to Mammalian Target of Rapamycin–Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation
por: Cuglievan, Branko, et al.
Publicado: (2018)

Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers
por: Kopetz, Scott, et al.
Publicado: (2019)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
por: Kato, Shumei, et al.
Publicado: (2015)

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations
por: Malhotra, Ankit, et al.
Publicado: (2015)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study
por: George, Goldy C, et al.
Publicado: (2019)

Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literature
por: Chen, Guocai, et al.
Publicado: (2015)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
por: Skinner, Heath D, et al.
Publicado: (2013)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
por: Seligson, Nathan D, et al.
Publicado: (2020)

Medication Reconciliation during Transitions of Care Across Institutions: A Quantitative Analysis of Challenges and Opportunities
por: Araya, Alejandro, et al.
Publicado: (2023)

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
por: Yap, Timothy A., et al.
Publicado: (2022)

Epithelial to mesenchymal transition is associated with rapamycin resistance
por: Holder, Ashley M., et al.
Publicado: (2015)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer
por: Gao, Ruli, et al.
Publicado: (2017)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

Biomedical informatics meets data science: current state and future directions for interaction
por: Payne, Philip R O, et al.
Publicado: (2018)

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
por: Subbiah, Vivek, et al.
Publicado: (2014)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_alb8vmtoe3fddfq4ktit2bvgvb